Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

Journal of Clinical Oncology

Volumn 20, Issue 22, 2002, Pages 4420-4427

  Orlowski, Robert Z ^a   Stinchcombe, Thomas E ^a   Mitchell, Beverly S ^a   Shea, Thomas C ^a   Baldwin, Albert S ^a   Stahl, Stephanie ^a   Adams, Julian ^a   Esseltine, Dixie Lee ^a   Elliott, Peter J ^a   Pien, Christine S ^a   Guerciolini, Roberto ^a   Anderson, Jessica K ^a   Depcik Smith, Natalie D ^a   Bhagat, Rita ^a   Lehman, Mary Jo ^a   Novick, Steven C ^a   O'Connor, Owen A ^a   Soignet, Steven L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; PARACETAMOL; PARAPROTEIN; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; RITUXIMAB; THALIDOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE;

ABDOMINAL DISTENSION; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG TOLERANCE; DYSPNEA; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; HYPERSENSITIVITY REACTION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; LEG EDEMA; LEUKOPENIA; MALAISE; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLASMA CELL DYSCRASIA; PLASMACYTOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RIGOR; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CYSTEINE ENDOPEPTIDASES; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TREATMENT OUTCOME; UNITED STATES;

EID: 0037111832     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.01.133     Document Type: Article

References (32)

1. Goldberg AL, Akopian TN, Kisselev AF, et al: New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem 378:131-140, 1997
2. Zwickl P, Baumeister W, Steven A: Dis-assembly lines: The proteasome and related ATPase-assisted proteases. Curr Opin Struct Biol 10:242-250, 2000
3. Ciechanover A, Orian A, Schwartz AL: Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays 22:442-451, 2000
4. Orlowski M, Wilk S: Catalytic activities of the 20 S proteasome: A multicatalytic proteinase complex. Arch Biochem Biophys 383:1-16, 2000
5. Hershko A: Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 9:788-799, 1997
6. Kloetzel PM: Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2:179-187, 2001
7. Oikawa T, Sasaki T, Nakamura M, et al: The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246:243-248, 1998
8. Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6:303-313, 1999
9. Grimm LM, Osborne BA: Apoptosis and the proteasome. Results Probl Cell Differ 23:209-228, 1999
10. Magnani M, Crinelli R, Bianchi M, et al: The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-κB (NF-κB). Curr Drug Targets 1:387-399, 2000
11. Imajoh-Ohmi KT, Sugiyama S, Tanaka K, et al: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217:1070-1077, 1995
12. Shinohara K, Tomioka M, Nakano H, et al: Apoptosis induction resulting from proteasome inhibition. Biochem J 317:385-388, 1996
13. Tanimoto Y, Onishi Y, Hashimoto S, et al: Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells. J Biochem (Tokyo) 121:542-549, 1997
14. Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94:855-860, 1997
15. Orlowski RZ, Eswara JR, Lafond-Walker A, et al: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348, 1998
16. Masdehors P, Omura S, Merle-Beral H, et al: Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 105:752-757, 1999
17. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
18. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622, 1999
19. Teicher BA, Ara G, Herbst R, et al: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638-2645, 1999
20. Lightcap ES, McCormack TA, Pien CS, et al: Proteasome inhibition measurements: Clinical application. Clin Chem 46:673-683, 2000
21. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
22. CTEP, NCI: Common Toxicity Criteria Manual, Version 2.0. Bethesda, MD, National Cancer Institute, 1999, pp 1-35
23. Millennium Pharmaceuticals: Investigator's Brochure: PS-341 (Ed 5). Cambridge, MA, Millennium Pharmaceuticals, 2001
24. Aghajanian C, Elliott P, Adams J, et al: Phase I trial of the proteasome inhibitor PS-341 in advanced malignancy. Proc Am Soc Clin Oncol 19:189a, 2000 (abstr 736)
25. Papandreou CN, Pagliaro L, Millikan R, et al: Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies. Proc Am Soc Clin Oncol 19:190a, 2000 (abstr 738)
26. Vanden Berghe W, Vermeulen L, De Wilde G, et al: Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 60:1185-1195, 2000
27. Tan C, Waldmann TA: Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 62:1083-1086, 2002
28. Riley TR III, Bhatti AM: Preventive strategies in chronic liver disease: Part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise. Am Fam Physician 64:1555-1560, 2001
29. Richardson PG, Berenson J, Irwin D, et al: Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 98:774a, 2001 (abstr 3223)
30. Papandreou C, Daliani D, Millikan RE, et al: Phase I study of intravenous proteasome inhibitor PS-341 in patients with advanced malignancies. Proc Am Soc Clin Oncol 20:86a, 2001 (abstr 340)
31. Anderson KC, Kyle RA, Dalton WS, et al: Multiple myeloma: New insights and therapeutic approaches. Hematology 2000, pp 147-165
32. Chauhan D, Uchiyama H, Akbarali Y, et al: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-1112, 1996